Skip to content

US · PLRX · BIOTECHNOLOGY

Pliant Therapeutics, Inc. (PLRX) intrinsic value and stock valuation

$0.60as of 2026-11-21 · Mkt cap 65.02M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pliant Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values PLRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PLRX’s statements →

Pliant Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 pliantrx.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-149.34M
20172025
Free cash flow
-$-128.71M
20172025
Total equity
$181.2M-8.5% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$1.58M$9.69M$7.57M
Operating income-$-150.07M-$-228.37M-$-184.15M-$-127.2M-$-97.53M
Net income-$-149.34M-$-210.3M-$-161.34M-$-123.32M-$-97.26M
EPSd-$-2.43M-$-3.47M-$-2.75M-$-2.93M-$-2.71M
Operating cash flow-$-128.34M-$-155.5M-$-116.36M-$-94.63M-$-75.44M
Capital expenditure-$-370K-$-3.85M-$-920K-$-1.76M-$-1.95M
Free cash flow-$-128.71M-$-159.35M-$-117.28M-$-96.39M-$-77.4M
Total assets$225.2M$397M$512.2M$350.6M$221.2M
Total debt$29.1M$60.2M$11.4M$15.8M$7.19M
Net debt-$-16.34M-$-11M-$-51.86M-$-17.87M-$-44.47M
Total equity$181.2M$304.1M$473.6M$313.3M$199.1M
Cash and short-term investments$190.9M$355.7M$494.3M$331.2M$200.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$1.58M$9.69M$7.57M
Cost of revenue$1.7M$0.00$0.00$0.00$0.00
Gross profit-$-1.7M$0.00$1.58M$9.69M$7.57M
Research and development expenses$109.2M$169.3M$127.8M$96.9M$77.6M
Selling, general and administrative expenses$47.2M$59.1M$57.9M$40M$27.6M
Other expenses-$-8M$0.00$0.00$0.00$0.00
Operating expenses$148.4M$228.4M$185.7M$136.9M$105.1M
Cost and expenses$150.1M$228.4M$185.7M$136.9M$105.1M
Interest income$0.00$21.1M$24.1M$4.67M$270K
Interest expense$2.56M$3.02M$1.27M$790K$0.00
Depreciation and amortization$1.7M$2.12M$1.84M$3.68M$1.53M
Ebitda-$-145.09M-$-205.16M-$-158.23M-$-118.85M-$-95.73M
Operating income-$-150.07M-$-228.37M-$-184.15M-$-127.2M-$-97.53M
Total other income/expenses, net$730K$18.1M$22.8M$3.88M$270K
Income before tax-$-149.34M-$-210.3M-$-161.34M-$-123.32M-$-97.26M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-149.34M-$-210.3M-$-161.34M-$-123.32M-$-97.26M
Weighted average shares outstanding$61.4M$60.5M$58.7M$42M$35.9M
Weighted average diluted shares outstanding$61.4M$60.5M$58.7M$42M$35.9M
Balance sheet
20252024202320222021
Cash and short-term investments$190.9M$355.7M$494.3M$331.2M$200.6M
Net receivables$820K$2.3M$3M$3.14M$2.47M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$196.5M$362.3M$505.5M$340.3M$209.4M
Property, plant and equipment, net$25M$32.8M$4.78M$9.91M$10.9M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$28.8M$34.7M$6.65M$10.3M$11.8M
Total assets$225.2M$397M$512.2M$350.6M$221.2M
Accounts payable$480K$5.96M$4.53M$1.58M$2.97M
Short-term debt$1.45M$540K$1.32M$2.46M$1.87M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$16.4M$33.2M$28.5M$23.9M$16.8M
Long-term debt$27.7M$59.7M$10.1M$13.4M$5.33M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$27.7M$59.7M$10.1M$13.4M$5.33M
Capital lease obligations$29.1M$30M$1.32M$5.89M$7.19M
Total liabilities$44M$92.9M$38.6M$37.3M$22.2M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-859.4M-$-710.05M-$-499.75M-$-338.41M-$-215.09M
Accumulated other comprehensive income (loss)-$-10K$320K$340K-$-1.96M-$-200K
Total equity$181.2M$304.1M$473.6M$313.3M$199.1M
Total investments$145.5M$284.5M$431M$297.5M$148.9M
Total debt$29.1M$60.2M$11.4M$15.8M$7.19M
Net debt-$-16.34M-$-11M-$-51.86M-$-17.87M-$-44.47M
Cash flow statement
20252024202320222021
Net income-$-149.34M-$-210.3M-$-161.34M-$-123.32M-$-97.26M
Depreciation and amortization$1.7M$2.12M$1.84M$1.82M$1.53M
Stock-based compensation$26.2M$37.6M$44.5M$22.6M$10.4M
Change in working capital-$-15.94M$9.09M$1.25M$4.22M$6.92M
Accounts receivable$0.00$0.00$1.98M$10K$7.28M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-5.48M$1.43M$2.97M-$-1.35M$890K
Net cash provided by operating activities-$-128.34M-$-155.5M-$-116.36M-$-94.63M-$-75.44M
Investments in property, plant and equipment-$-370K-$-3.85M-$-920K-$-1.76M-$-1.95M
Acquisitions, net$150K$0.00$0.00$148.4M-$-75.65M
Net cash used for investing activities$134.3M$140.3M-$-127.01M-$-150.2M$73.7M
Common stock issued$570K$3.21M$275.3M$215.6M$2.98M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-31.7M$23.1M$274.4M$226.9M$2.53M
Net change in cash-$-25.74M$7.95M$31M-$-17.98M$780K
Cash at end of period$46.9M$72.7M$64.7M$33.7M$51.7M
Operating cash flow-$-128.34M-$-155.5M-$-116.36M-$-94.63M-$-75.44M
Capital expenditure-$-370K-$-3.85M-$-920K-$-1.76M-$-1.95M
Free cash flow-$-128.71M-$-159.35M-$-117.28M-$-96.39M-$-77.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pliant Therapeutics, Inc.

        Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

        CEO
        Bernard Coulie
        Employees
        49
        Beta
        1.22

        Explore

        Frequently asked questions

        What is the intrinsic value of Pliant Therapeutics, Inc. (PLRX)?

        InvestorsCraft does not currently publish an intrinsic value for PLRX. How the IC value is calculated.

        Is PLRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for PLRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.